Provectus presents update on PV-10 drug at European Cancer Congress
Knoxville-based Provectus Pharmaceuticals, Inc., presented detailed findings from the Phase 2 trial of its PV-10 drug yesterday at the “European Cancer Congress 2013” in Amsterdam, The Netherlands. For more information, read the company’s news release.
Like what you've read?
Forward to a friend!